AI+ Media Development Platform AlfaOPA Officially Launched
Great Bay Bio successfully hosted the Future Technology: AI Empowering Bioprocessing Development summit at the Suzhou International Expo Center, marking a celebration of technological innovation. The event saw the official introduction of AlfaOPA™, an AI-enabled culture media development platform developed by Great Bay Bio. This platform revolutionizes traditional culture media development by integrating AI to optimize culture media, eliminating the need for blind screening.
The launch of AlfaOPA™ is a significant step forward for
Great Bay Bio's CMC platform, advancing its AI-driven cell engineering
capabilities. This platform signifies the completion of a comprehensive
business system centered around "cell engineering," incorporating
"cell line construction" and "culture media development."
AlfaOPA™ combines Great Bay Bio's dry and wet experimental
platforms to create metabolic models for multiple cell lines. Through
comparisons and simulations, optimized supplements are generated, streamlining
culture media development. This platform is adaptable to various cell lines
without requiring the replacement of existing media. Initial customer data
reveals an average over 30% increase in protein expression level for formulas
optimized with AlfaOPA™, while maintaining consistent protein quality.
Kingsley Leung, GBB's chairman and co-founder, expressed his
enthusiasm for discussing the industry's future in Suzhou. AlfaOPA™ aligns with
Great Bay Bio's goal of enhancing drug development productivity through
technological innovation and market-driven demand. This AI-driven culture media
development platform, combined with their site-specific integration cell line
platform, maximizes product potential. The launch of AlfaOPA™ ushers in a new
era in AI-powered culture media development technology, emphasizing its
market-oriented approach.
Comments
Post a Comment